Return to content in this issue
Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab
Gamboa P1,2, Galán C1, Arrien A1, Segurola A1,2, Jáuregui I1,2
1Allergy Department, Hospital Universitario Cruces, Barakaldo, Spain
2Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain
J Investig Allergol Clin Immunol 2024; Vol 34(1)
: 68-70
doi: 10.18176/jiaci.0926
Key words: Idiopathic bradykinergic angioedema, Landelumab, C1 inhibitor